Our investors, scientific and clinical advisors are key to our success

In 2012 Karus secured a £25 million ($39 million) Series B investment led by SV Life Sciences (now SV Health Investors), New Leaf Ventures, Novo A/S and International Biotechnology Trust, who joined existing investors, IP Group and several Business Angels. This investment is being used to advance KA2237 and KA2507 from concept to clinic.

In October 2018 Karus secured an additional £12 million from SV Health Investors, New Leaf Ventures, Novo A/S and several pre-existing individual investors and Business Angels.